Qualification Consortium News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Qualification Consortium. Real-time updates on events, politics, business and more.

Drug Candidate for Schizophrenia, Alzheimer Disease Approved to Initiate Phase 2 Trial in Q2 2024

January 26, 2024

The candidate also aims to address neurodevelopmental and neurodegenerative disorders such as Parkinson disease and Rett syndrome.

Christopheru Missling Biomarker Qualification Consortium Anavex Life Sciences Corp Us Food Drug Administration Drug Administration Karuna Therapeutic

Source: psychiatrictimes.com

Pharma Consortium Publishes Results of Large EEG/ERP Biomarker Study in Subjects with Schizophrenia and Healthy Volunteers

March 16, 2023

/PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today the publication of all data (https://doi.org/10.1016/j.schres.2023.02.018) from a...

Marco Cecchi Larry Ereshefsky Daniel Javitt Clinical Sciences At Cenexel Biomarker Qualification Consortium York State Psychiatric Institute

Source: prnewswire.com

Pharma Industry Consortium Completes Brain Wave Study of Ketamine Effects on Healthy Volunteers

March 1, 2023

/PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the...

Dan Mathalon Marco Cecchi Atai Life Sciences Columbia University Cenexel Hassman Research Institute Biomarker Qualification Consortium

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Qualification Consortium News Today

Drug Candidate for Schizophrenia, Alzheimer Disease Approved to Initiate Phase 2 Trial in Q2 2024

Pharma Consortium Publishes Results of Large EEG/ERP Biomarker Study in Subjects with Schizophrenia and Healthy Volunteers

Pharma Industry Consortium Completes Brain Wave Study of Ketamine Effects on Healthy Volunteers

Explore More Categories